top of page
Executive Spotlights

Latigo Biotherapeutics launches with $135M Series A funding to advance development of non-opioid pain treatments

Thousands Oaks, CA, February 14, 2024 (PRNewswire) -- Latigo Biotherapeutics has announced that it has completed a $135 million series A financing round.  The company was incubated by Westlake Village BioPartners which also spearheaded the series A funding alongside co-leads 5AM Ventures and Foresite Capital, with additional participation from Corner Ventures.  Inc.   Latigo is focused on non-opioid pain treatments targeting pain at its root.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page